Parallax Volatility Advisers’s CRISPR Therapeutics CRSP Stock Holding History

Parallax Volatility Advisers’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-25,000	Closed	-$1.62M	–	1677
2025 Q3	$1.62M	Hold	25,000	–	–	﹤0.01%	983
2025 Q2	$1.22M	Buy	+25,000	New	+$967K	﹤0.01%	1011
2024 Q1	–	Sell	-200	Closed	-$12.5K	–	1921
2023 Q4	$12.5K	Sell	200 -45,000	-100%	-$2.49M	﹤0.01%	2013
2023 Q3	$2.05M	Buy	45,200 +200	+0.4%	+$10.3K	﹤0.01%	1089
2023 Q2	$2.53M	Sell	45,000 -14,600	-24%	-$828K	0.01%	1045
2023 Q1	$2.7M	Buy	59,600 +44,700	+300%	+$2.17M	0.01%	1130
2022 Q4	$606K	Sell	14,900 -1,500	-9%	-$79.6K	﹤0.01%	1826
2022 Q3	$1.07M	Buy	16,400 +400	+3%	+$29K	﹤0.01%	1710
2022 Q2	$973K	Sell	16,000 -15,000	-48%	-$882K	﹤0.01%	1660
2022 Q1	$1.95M	Buy	+31,000	New	+$1.95M	﹤0.01%	1373

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

GSK plc London $599M AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parallax Volatility Advisers's CRSP Position: Q4 2025 in Review

Parallax Volatility Advisers sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 635 shares — an estimated $41.2K sold.

Parallax Volatility Advisers first reported a position in CRSP in Q1 2022 and held it in 6 quarters. The position peaked at $1.6M in Q1 2022. 479 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

Parallax Volatility Advisers reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
Parallax Volatility Advisers sold 635 CRISPR Therapeutics shares in Q4 2025, an estimated $41.2K.
Parallax Volatility Advisers first reported a position in CRISPR Therapeutics in Q1 2022 and held it in 6 quarters.
Parallax Volatility Advisers's CRISPR Therapeutics position peaked at $1.6M in Q1 2022.
479 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Parallax Volatility Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.